SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    S. Muzerengi, C. Herd, C. Rick, C.E. Clarke, A systematic review of interventions to reduce hospitalisation in Parkinson's disease, Parkinsonism & Related Disorders, 2016, 24, 3

    CrossRef

  2. 2
    Achraf Benba, Abdelilah Jilbab, Ahmed Hammouch, Analysis of multiple types of voice recordings in cepstral domain using MFCC for discriminating between patients with Parkinson’s disease and healthy people, International Journal of Speech Technology, 2016,

    CrossRef

  3. 3
    Cristina Linares, Pablo Martinez-Martin, Carmen Rodríguez-Blázquez, Maria João Forjaz, Rocío Carmona, Julio Díaz, Effect of heat waves on morbidity and mortality due to Parkinson's disease in Madrid: A time-series analysis, Environment International, 2016, 89-90, 1

    CrossRef

  4. 4
    Yu-Feng Huang, Yi-Chun Chou, Chun-Chieh Yeh, Chaur-Jong Hu, Yih-Giun Cherng, Ta-Liang Chen, Chien-Chang Liao, Outcomes After Non-neurological Surgery in Patients With Parkinsonʼs Disease, Medicine, 2016, 95, 12, e3196

    CrossRef

  5. 5
    Elan D. Louis, Claire Henchcliffe, Brian T. Bateman, H. Christian Schumacher, Young-onset Parkinson's disease: Hospital utilization and medical comorbidity in a nationwide survey, Movement Disorders, 2016, 31, 4
  6. 6
    Victoria A Goodwin, Ruth Pickering, Claire Ballinger, Helen Roberts, Emma McIntosh, Sarah Lamb, Alice Nieuwboer, Lynn Rochester, Ann Ashburn, A multi-centre, randomised controlled trial of the effectiveness of PDSAFE to prevent falls among people with Parkinson’s: study protocol, BMC Neurology, 2015, 15, 1

    CrossRef

  7. 7
    C.J. Lobb, D. Jaeger, Bursting activity of substantia nigra pars reticulata neurons in mouse parkinsonism in awake and anesthetized states, Neurobiology of Disease, 2015, 75, 177

    CrossRef

  8. 8
    Marcel M. Miyake, Benjamin S. Bleier, Bypassing the blood–brian barrier using established skull base reconstruction techniques, World Journal of Otorhinolaryngology-Head and Neck Surgery, 2015, 1, 1, 11

    CrossRef

  9. 9
    Ju Young Shin, Barbara Habermann, Ingrid Pretzer-Aboff, Challenges and strategies of medication adherence in Parkinson's disease: A qualitative study, Geriatric Nursing, 2015, 36, 3, 192

    CrossRef

  10. 10
    LA King, DS Peterson, M. Mancini, P. Carlson-Kuhta, BW Fling, K. Smulders, JG Nutt, M. Dale, J. Carter, KM Winters-Stone, FB Horak, Do cognitive measures and brain circuitry predict outcomes of exercise in Parkinson Disease: a randomized clinical trial, BMC Neurology, 2015, 15, 1

    CrossRef

  11. 11
    Carmen Rodríguez-Blázquez, Maria João Forjaz, Luis Lizán, Silvia Paz, Pablo Martínez-Martín, Estimating the direct and indirect costs associated with Parkinson’s disease, Expert Review of Pharmacoeconomics & Outcomes Research, 2015, 15, 6, 889

    CrossRef

  12. 12
    Y.-F. Huang, Y.-G. Cherng, S. P. C. Hsu, C.-C. Yeh, Y.-C. Chou, C.-H. Wu, T.-L. Chen, C.-C. Liao, Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies, Osteoporosis International, 2015, 26, 6, 1723

    CrossRef

  13. 13
    C.J. Lobb, Abnormal bursting as a pathophysiological mechanism in Parkinson's disease, Basal Ganglia, 2014, 3, 4, 187

    CrossRef

  14. 14
    Jane Larkindale, Wenya Yang, Paul F. Hogan, Carol J. Simon, Yiduo Zhang, Anjali Jain, Elizabeth M. Habeeb-Louks, Annie Kennedy, Valerie A. Cwik, Cost of illness for neuromuscular diseases in the United States, Muscle & Nerve, 2014, 49, 3
  15. 15
    Samuel M. Goldman, Environmental Toxins and Parkinson's Disease, Annual Review of Pharmacology and Toxicology, 2014, 54, 1, 141

    CrossRef

  16. 16
    He-Jin Lee, Eun-Jin Bae, Seung-Jae Lee, Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases, Nature Reviews Neurology, 2014, 10, 2, 92

    CrossRef

  17. 17
    Richard Dodel, Bengt Jönsson, Jens Peter Reese, Yaroslav Winter, Pablo Martinez-Martin, Robert Holloway, Cristina Sampaio, Evžen Růžička, Graeme Hawthorne, Wolfgang Oertel, Werner Poewe, Glenn Stebbins, Oliver Rascol, Christopher G. Goetz, Anette Schrag, Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease, Movement Disorders, 2014, 29, 2
  18. 18
    Mauro Castelli, Leonardo Vanneschi, Sara Silva, Prediction of the Unified Parkinson’s Disease Rating Scale assessment using a genetic programming system with geometric semantic genetic operators, Expert Systems with Applications, 2014, 41, 10, 4608

    CrossRef

  19. 19
    Francine Johansson Azeredo, Teresa Dalla Costa, Hartmut Derendorf, Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions, Clinical Pharmacokinetics, 2014, 53, 3, 205

    CrossRef

  20. 20
    Don A. Yungher, Tiffany R. Morris, Valentina Dilda, James M. Shine, Sharon L. Naismith, Simon J. G. Lewis, Steven T. Moore, Temporal Characteristics of High-Frequency Lower-Limb Oscillation during Freezing of Gait in Parkinson’s Disease, Parkinson's Disease, 2014, 2014, 1

    CrossRef

  21. 21
    Eun Sook Bae, Sang Myung Chun, Jae Woo Kim, Chang Wan Kang, A Prediction Model for Depression in Patients with Parkinson's Disease, Korean Journal of Health Education and Promotion, 2013, 30, 5, 139

    CrossRef

  22. 22
    Scott J. Johnson, Melissa D. Diener, Anna Kaltenboeck, Howard G. Birnbaum, Andrew D. Siderowf, An economic model of Parkinson's disease: Implications for slowing progression in the United States, Movement Disorders, 2013, 28, 3
  23. 23
    Yu-Jung Wei, Francis B. Palumbo, Linda Simoni-Wastila, Lisa M. Shulman, Bruce Stuart, Robert Beardsley, Clayton Brown, Antiparkinson Drug Use and Adherence in Medicare Part D Beneficiaries With Parkinson’s Disease, Clinical Therapeutics, 2013, 35, 10, 1513

    CrossRef

  24. 24
    Sandipan Bhattacharjee, Usha Sambamoorthi, Co-occurring chronic conditions and healthcare expenditures associated with Parkinson's disease: A propensity score matched analysis, Parkinsonism & Related Disorders, 2013, 19, 8, 746

    CrossRef

  25. 25
    Erin R. Foster, Laura Golden, Ryan P. Duncan, Gammon M. Earhart, Community-Based Argentine Tango Dance Program Is Associated With Increased Activity Participation Among Individuals With Parkinson's Disease, Archives of Physical Medicine and Rehabilitation, 2013, 94, 2, 240

    CrossRef

  26. 26
    Florent F. Richy, Guilhem Pietri, Kimberly A. Moran, Emmanuelle Senior, Lydia E. Makaroff, Compliance with Pharmacotherapy and Direct Healthcare Costs in Patients with Parkinson’s Disease: A Retrospective Claims Database Analysis, Applied Health Economics and Health Policy, 2013, 11, 4, 395

    CrossRef

  27. 27
    Scott J. Johnson, Anna Kaltenboeck, Melissa Diener, Howard G. Birnbaum, ElizaBeth Grubb, Jane Castelli-Haley, Andrew D. Siderowf, Costs of Parkinson’s Disease in a Privately Insured Population, PharmacoEconomics, 2013, 31, 9, 799

    CrossRef

  28. 28
    Y. J. Zhao, L. C. S. Tan, W. L. Au, D. M. K. Heng, I. A. L. Soh, S. C. Li, N. Luo, H. L. Wee, Estimating the lifetime economic burden of Parkinson's disease in Singapore, European Journal of Neurology, 2013, 20, 2
  29. 29
    Anhar Hassan, Samuel S. Wu, Peter Schmidt, Yunfeng Dai, Tanya Simuni, Nir Giladi, Bastiaan R. Bloem, Irene A. Malaty, Michael S. Okun, High rates and the risk factors for emergency room visits and hospitalization in Parkinson's disease, Parkinsonism & Related Disorders, 2013, 19, 11, 949

    CrossRef

  30. 30
    Ju Young Shin, Cristina C. Hendrix, Management of patients with Parkinson disease, The Nurse Practitioner, 2013, 38, 10, 34

    CrossRef

  31. 31
    R. Murphy, N. Tubridy, H. Kevelighan, S. O’Riordan, Parkinson’s disease: how is employment affected?, Irish Journal of Medical Science, 2013, 182, 3, 415

    CrossRef

  32. 32
    Samuel D. Kim, Natalie E. Allen, Colleen G. Canning, Victor S. C. Fung, Postural Instability in Patients with Parkinson’s Disease, CNS Drugs, 2013, 27, 2, 97

    CrossRef

  33. 33
    Carlos Zúñiga-Ramírez, Federico Micheli, Preladenant: an adenosine A2Areceptor antagonist for Parkinson’s disease, Future Neurology, 2013, 8, 6, 639

    CrossRef

  34. 34
    M.P. Cunha, M.D. Martín-de-Saavedra, A. Romero, E. Parada, J. Egea, L. del Barrio, A.L.S. Rodrigues, M.G. López, Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways, Neuroscience, 2013, 238, 185

    CrossRef

  35. 35
    Stacey L. Kowal, Timothy M. Dall, Ritashree Chakrabarti, Michael V. Storm, Anjali Jain, The current and projected economic burden of Parkinson's disease in the United States, Movement Disorders, 2013, 28, 3
  36. 36
    Victoria Divino, Mitch DeKoven, John H. Warner, Joseph Giuliano, Karen E. Anderson, Douglas Langbehn, Won Chan Lee, The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysis, Journal of Medical Economics, 2013, 16, 8, 1043

    CrossRef

  37. 37
    Liancai Mu, Stanislaw Sobotka, Jingming Chen, Hungxi Su, Ira Sanders, Charles H. Adler, Holly A. Shill, John N. Caviness, Johan E. Samanta, Thomas G. Beach, Altered Pharyngeal Muscles in Parkinson Disease, Journal of Neuropathology & Experimental Neurology, 2012, 71, 6, 520

    CrossRef

  38. 38
    Weiqi Zhang, Shunlei Duan, Ying Li, Xiuling Xu, Jing Qu, Weizhou Zhang, Guang-Hui Liu, Converted neural cells: induced to a cure?, Protein & Cell, 2012, 3, 2, 91

    CrossRef

  39. 39
    A. Kaltenboeck, S.J. Johnson, M.R. Davis, H.G. Birnbaum, C.A. Carroll, M.L. Tarrants, A.D. Siderowf, Direct costs and survival of medicare beneficiaries with early and advanced parkinson’s disease, Parkinsonism & Related Disorders, 2012, 18, 4, 321

    CrossRef

  40. 40
    J. Lökk, S. Borg, J. Svensson, U. Persson, G. Ljunggren, Drug and treatment costs in Parkinson’s disease patients in Sweden, Acta Neurologica Scandinavica, 2012, 125, 2
  41. You have free access to this content41
    Siok Bee Tan, Allison F Williams, Meg E Morris, Experiences of caregivers of people with Parkinson’s disease in Singapore: a qualitative analysis, Journal of Clinical Nursing, 2012, 21, 15-16
  42. 42
    Douglas E. Hobson, Lisa M. Lix, Mahmoud Azimaee, William D. Leslie, Charles Burchill, Shaun Hobson, Healthcare utilization in patients with Parkinson's disease: A population-based analysis, Parkinsonism & Related Disorders, 2012, 18, 8, 930

    CrossRef

  43. 43
    Ariane Park, Mark Stacy, Istradefylline for the treatment of Parkinson's disease, Expert Opinion on Pharmacotherapy, 2012, 13, 1, 111

    CrossRef

  44. 44
    Barbara Jasinska-Myga, Michael G. Heckman, Christian Wider, John D. Putzke, Zbigniew K. Wszolek, Ryan J. Uitti, Loss of ability to work and ability to live independently in Parkinson’s disease, Parkinsonism & Related Disorders, 2012, 18, 2, 130

    CrossRef

  45. 45
    Munazza Sophie, Blair Ford, Management of Pain in Parkinson’s Disease, CNS Drugs, 2012, 26, 11, 937

    CrossRef

  46. 46
    Jens P Reese, Judith Dams, Yaroslav Winter, Monika Balzer-Geldsetzer, Wolfgang H Oertel, Richard Dodel, Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease, Expert Opinion on Pharmacotherapy, 2012, 13, 7, 939

    CrossRef

  47. 47
    Meg E Morris, Clarissa Martin, Jennifer L McGinley, Frances E Huxham, Hylton B Menz, Nicholas F Taylor, Mary Danoudis, Jennifer J Watts, Sze-Ee Soh, Andrew H Evans, Malcolm Horne, Peter Kempster, Protocol for a home-based integrated physical therapy program to reduce falls and improve mobility in people with Parkinson’s disease, BMC Neurology, 2012, 12, 1, 54

    CrossRef

  48. 48
    Roger Ghoche, The conceptual framework of palliative care applied to advanced Parkinson’s disease, Parkinsonism & Related Disorders, 2012, 18, S2

    CrossRef

  49. 49
    M.P. Zanin, L.N. Pettingill, A.R. Harvey, D.F. Emerich, C.G. Thanos, R.K. Shepherd, The development of encapsulated cell technologies as therapies for neurological and sensory diseases, Journal of Controlled Release, 2012, 160, 1, 3

    CrossRef

  50. 50
    Dong-Churl Suh, Rajesh Pahwa, Usha Mallya, Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia, Journal of the Neurological Sciences, 2012, 319, 1-2, 24

    CrossRef

  51. 51
    J. Paul Leigh, James P. Marcin, Workersʼ Compensation Benefits and Shifting Costs for Occupational Injury and Illness, Journal of Occupational and Environmental Medicine, 2012, 54, 4, 445

    CrossRef

  52. 52
    Anli A. Liu, Christine E. Boxhorn, Michael A. Klufas, Paul J. Christos, Jeffrey T. Thorne, Angela Y. Shih, Nadejda M. Tsankova, Benjamin J. Dorfman, Claire Henchcliffe, Panida Piboolnurak, Melissa J. Nirenberg, Clinical predictors of frequent patient telephone calls in Parkinson’s disease, Parkinsonism & Related Disorders, 2011, 17, 2, 95

    CrossRef

  53. 53
    Oliver H.H. Gerlach, Ania Winogrodzka, Wim E.J. Weber, Clinical problems in the hospitalized Parkinson's disease patient: Systematic review, Movement Disorders, 2011, 26, 2
  54. 54
    L. B. Gerson, M. Bonafede, N. Princic, C. Gregory, A. Farr, S. Balu, Development of a refractory gastro-oesophageal reflux score using an administrative claims database, Alimentary Pharmacology & Therapeutics, 2011, 34, 5
  55. 55
    Y. J. Zhao, L. C. S. Tan, S. C. Li, W. L. Au, S. H. Seah, P. N. Lau, N. Luo, H. L. Wee, Economic burden of Parkinson’s disease in Singapore, European Journal of Neurology, 2011, 18, 3
  56. 56
    Jongpil Kim, Susan C. Su, Haoyi Wang, Albert W. Cheng, John P. Cassady, Michael A. Lodato, Christopher J. Lengner, Chee-Yeun Chung, Meelad M. Dawlaty, Li-Huei Tsai, Rudolf Jaenisch, Functional Integration of Dopaminergic Neurons Directly Converted from Mouse Fibroblasts, Cell Stem Cell, 2011, 9, 5, 413

    CrossRef

  57. 57
    Demetrius M. Maraganore, Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease, Journal of Movement Disorders, 2011, 4, 1, 1

    CrossRef

  58. 58
    Lawrence Elmer, Robert A Hauser, Strategies for Parkinson’s disease care: prevention and management of motor fluctuations, Neurodegenerative Disease Management, 2011, 1, 5, 415

    CrossRef

  59. 59
    Leslie J. Findley, Eifiona Wood, Julia Lowin, Claudia Roeder, Annika Bergman, Mathias Schifflers, The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset, Journal of Medical Economics, 2011, 14, 1, 130

    CrossRef

  60. 60
    Andreas Charidimou, John Seamons, Caroline Selai, Anette Schrag, The Role of Cognitive-Behavioural Therapy for Patients with Depression in Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  61. 61
    Scellig Stone, Karim Mukhida, Andres M. Lozano, Youmans Neurological Surgery, 2011,

    CrossRef

  62. 62
    Oscar S. Gershanik, Clinical problems in late-stage Parkinson’s disease, Journal of Neurology, 2010, 257, S2, 288

    CrossRef

  63. 63
    Yaroslav Winter, Sonja von Campenhausen, Hana Brozova, Jana Skoupa, Jens P. Reese, Kai Bötzel, Karla Eggert, Wolfgang H. Oertel, Richard Dodel, Evzen Ruzicka, Costs of Parkinson's disease in Eastern Europe: A Czech cohort study, Parkinsonism & Related Disorders, 2010, 16, 1, 51

    CrossRef

  64. 64
    Marcy L. Tarrants, Michel F. Denarié, Jane Castelli-Haley, Jennifer Millard, Dongmu Zhang, Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence, The American Journal of Geriatric Pharmacotherapy, 2010, 8, 4, 374

    CrossRef

  65. 65
    George D Mellick, Peter A Silburn, Greg T Sutherland, Gerhard A Siebert, Exploiting the potential of molecular profiling in Parkinson’s disease: current practice and future probabilities, Expert Review of Molecular Diagnostics, 2010, 10, 8, 1035

    CrossRef

  66. 66
    Perla Werner, Amos D. Korczyn, Lay persons' beliefs and knowledge about Parkinson's disease: Prevalence and socio-demographic correlates, Parkinsonism & Related Disorders, 2010, 16, 6, 415

    CrossRef

  67. 67
    C. Vossius, O. B. Nilsen, J. P. Larsen, Parkinson’s disease and hospital admissions: frequencies, diagnoses and costs, Acta Neurologica Scandinavica, 2010, 121, 1
  68. 68
    Mehdi Shafiee Ar, Parkinson’s Disease, the Inflammatory Pathway and Anti-Inflammatory Drugs: An Overview, Journal of Medical Sciences(Faisalabad), 2010, 10, 3, 49

    CrossRef

  69. 69
    Michael S. Okun, Andrew Siderowf, John G. Nutt, Gerald T. O’Conner, Bastiaan R. Bloem, Elaine M. Olmstead, Mark Guttman, Tanya Simuni, Eric Cheng, Elaine V. Cohen, Sotirios Parashos, Laura Marsh, Irene A. Malaty, Nir Giladi, Peter Schmidt, Joyce Oberdorf, Piloting the NPF data-driven quality improvement initiative, Parkinsonism & Related Disorders, 2010, 16, 8, 517

    CrossRef

  70. 70
    Keith L. Davis, Heather M. Edin, Jeffery K. Allen, Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data, Movement Disorders, 2010, 25, 4
  71. 71
    C. Okan Sakar, Olcay Kursun, Telediagnosis of Parkinson’s Disease Using Measurements of Dysphonia, Journal of Medical Systems, 2010, 34, 4, 591

    CrossRef

  72. 72
    William Macaulay, Jeffrey A. Geller, Anthony R. Brown, Lucien J. Cote, Howard A. Kiernan, Total Knee Arthroplasty and Parkinson Disease: Enhancing Outcomes and Avoiding Complications, American Academy of Orthopaedic Surgeon, 2010, 18, 11, 687

    CrossRef

  73. 73
    Huybert Groenendaal, Marcy L. Tarrants, Christophe Armand, Treatment of Advanced Parkinsonʼs Disease in the United States, Clinical Drug Investigation, 2010, 30, 11, 789

    CrossRef

  74. 74
    Yaroslav Winter, Monika Balzer-Geldsetzer, Sonja von Campenhausen, Annika Spottke, Karla Eggert, Wolfgang H. Oertel, Richard Dodel, Trends in resource utilization for Parkinson's disease in Germany, Journal of the Neurological Sciences, 2010, 294, 1-2, 18

    CrossRef

  75. 75
    Guvenc Kockaya, Albert Wertheimer, What are the top most costly diseases for USA? The alignment of burden of illness with prevention and screening expenditures, Health, 2010, 02, 10, 1174

    CrossRef

  76. 76
    Astrid Larisch, Wolfgang H. Oertel, Karla Eggert, Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson’s disease. A National Survey of German neurologists in private practice, Journal of Neurology, 2009, 256, 10, 1681

    CrossRef

  77. 77
    Yaroslav Winter, Sonja von Campenhausen, Georgy Popov, Jens P. Reese, Jens Klotsche, Kai Bötzel, Eugene Gusev, Wolfgang H. Oertel, Richard Dodel, Alla Guekht, Costs of Illness in a Russian Cohort of Patients with Parkinsonʼs Disease, PharmacoEconomics, 2009, 27, 7, 571

    CrossRef

  78. 78
    Sonja von Campenhausen, Yaroslav Winter, Julia Gasser, Klaus Seppi, Jens-P. Reese, Karl-P. Pfeiffer, Sabine Geiger-Gritsch, Kai Bötzel, Uwe Siebert, Wolfgang H. Oertel, Richard Dodel, Werner Poewe, Krankheitskosten und Versorgungssituation bei Morbus Parkinson – eine Analyse in Österreich, Wiener klinische Wochenschrift, 2009, 121, 17-18, 574

    CrossRef

  79. 79
    Rajesh Pahwa, Kelly E. Lyons, Levodopa-related wearing-off in Parkinson's disease: identification and management, Current Medical Research and Opinion, 2009, 25, 4, 841

    CrossRef

  80. 80
    C. Vossius, O. B. Nilsen, J. P. Larsen, Parkinson’s disease and nursing home placement: the economic impact of the need for care, European Journal of Neurology, 2009, 16, 2
  81. 81
    Mark P. Mattson, Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders, Experimental Gerontology, 2009, 44, 10, 625

    CrossRef

  82. 82
    M.A. Little, P.E. McSharry, E.J. Hunter, J. Spielman, L.O. Ramig, Suitability of Dysphonia Measurements for Telemonitoring of Parkinson's Disease, IEEE Transactions on Biomedical Engineering, 2009, 56, 4, 1015

    CrossRef

  83. 83
    Ludy Shih, Daniel Tarsy, Pharmacology and Therapeutics, 2009,

    CrossRef

  84. 84
    A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease, Clinical Neuropharmacology, 2008, 31, 3, 141

    CrossRef

  85. 85
    O. Riedel, J. Klotsche, A. Spottke, G. Deuschl, H. Förstl, F. Henn, I. Heuser, W. Oertel, H. Reichmann, P. Riederer, C. Trenkwalder, R. Dodel, H.-U. Wittchen, Cognitive impairment in 873 patients with idiopathic Parkinson's disease, Journal of Neurology, 2008, 255, 2, 255

    CrossRef

  86. 86
    Karla M Eggert, Jens P Reese, Wolfgang H Oertel, Richard Dodel, Cost Effectiveness of Pharmacotherapies in Early Parkinson’s Disease, CNS Drugs, 2008, 22, 10, 841

    CrossRef

  87. 87
    Antonio P. Vargas, Antonio P. Vargas, Francisco J. Carod-Artal, Simone V. Nunes, Miriam Melo, Disability and use of healthcare resources in Brazilian patients with Parkinson's disease, Disability and Rehabilitation, 2008, 30, 14, 1055

    CrossRef

  88. 88
    Hervé Allain, Danièle Bentué-Ferrer, Yvette Akwa, Disease-modifying drugs and Parkinson's disease, Progress in Neurobiology, 2008, 84, 1, 25

    CrossRef

  89. 89
    Becky G. Farley, Cynthia M. Fox, Lorraine O. Ramig, David H. McFarland, Intensive Amplitude-specific Therapeutic Approaches for Parkinsonʼs Disease, Topics in Geriatric Rehabilitation, 2008, 24, 2, 99

    CrossRef

  90. 90
    Amit S. Kulkarni, Rajesh Balkrishnan, Roger T. Anderson, Heather M. Edin, Jeff Kirsch, Mark A. Stacy, Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease, Movement Disorders, 2008, 23, 3
  91. 91
    Atheir Abbas, Bryan L Roth, Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders, Expert Opinion on Pharmacotherapy, 2008, 9, 18, 3251

    CrossRef

  92. 92
    André Toulouse, Aideen M. Sullivan, Progress in Parkinson's disease—Where do we stand?, Progress in Neurobiology, 2008, 85, 4, 376

    CrossRef

  93. 93
    Lorraine O Ramig, Cynthia Fox, Shimon Sapir, Speech treatment for Parkinson’s disease, Expert Review of Neurotherapeutics, 2008, 8, 2, 297

    CrossRef

  94. 94
    Chris Mason, Peter Dunnill, The strong financial case for regenerative medicine and the regen industry, Regenerative Medicine, 2008, 3, 3, 351

    CrossRef

  95. 95
    J. Paul Leigh, Marion Gillen, Peter Franks, Susan Sutherland, Hien H. Nguyen, Kyle Steenland, Guibo Xing, Costs of needlestick injuries and subsequent hepatitis and HIV infection, Current Medical Research and Opinion, 2007, 23, 9, 2093

    CrossRef

  96. 96
    Leslie J. Findley, The economic impact of Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, S8

    CrossRef

  97. 97
    Matthias Fargel, Bernd Grobe, Eberhard Oesterle, Claudia Hastedt, Markus Rupp, Treatment of Parkinson???s Disease, Clinical Drug Investigation, 2007, 27, 3, 207

    CrossRef

  98. 98
    Gang Wang, Qi Cheng, Rui Zheng, Yu-Yan Tan, Xiao-Kang Sun, Hai-Yan Zhou, Xiao-Lai Ye, Ying Wang, Zeng Wang, Bo-Min Sun, Sheng-Di Chen, Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China, Movement Disorders, 2006, 21, 9
  99. 99
    John C Morgan, Kapil D Sethi, Emerging drugs for Parkinson’s disease, Expert Opinion on Emerging Drugs, 2006, 11, 3, 403

    CrossRef

  100. 100
    Kirsti K. Martikainen, Tiina H. Luukkaala, Reijo J. Marttila, Parkinson's disease and working capacity, Movement Disorders, 2006, 21, 12
  101. 101
    John C Morgan, Kapil D Sethi, Rotigotine for the treatment of Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 9, 1275

    CrossRef

  102. 102
    Gammon M. Earhart, Michael J. Falvo, Parkinson Disease and Exercise, Comprehensive Physiology,
  103. 103
    Samuel M. Goldman, Parkinson's Disease,